MP
CEROW

Mangrove Partners’s CERo Therapeutics Warrants CEROW Stock Holding History

Mangrove Partners’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-163,538
Closed -$1.78M – 175
2023
Q2 		$1.78M Hold
163,538
– – 0.12% 143
2023
Q1 		$1.75M Hold
163,538
– – 0.11% 166
2022
Q4 		$1.68M Hold
163,538
– – 0.09% 227
2022
Q3 		$1.65M Hold
163,538
– – 0.1% 243
2022
Q2 		$1.64M Hold
163,538
– – 0.08% 346
2022
Q1 		$1.64M Hold
163,538
– – 0.09% 329
2021
Q4 		$1.62M Buy
+163,538
New +$75.4K 0.1% 384

Other funds holding CEROW

PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Mangrove Partners's CEROW Position: Q3 2023 in Review

Mangrove Partners sold out of CERo Therapeutics Warrants (CEROW) in Q3 2023, closing a stake of 163,538 shares — an estimated $1.78M sold.

Mangrove Partners first reported a position in CEROW in Q4 2021 and held it in 7 quarters. The position peaked at $1.78M in Q2 2023. 43 funds tracked by Wall St. Rank hold CEROW as of Q3 2023.

  • Mangrove Partners reported no remaining CERo Therapeutics Warrants position as of Q3 2023 after selling out during the quarter.
  • Mangrove Partners sold 163,538 CERo Therapeutics Warrants shares in Q3 2023, an estimated $1.78M.
  • Mangrove Partners first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 7 quarters.
  • Mangrove Partners's CERo Therapeutics Warrants position peaked at $1.78M in Q2 2023.
  • 43 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q3 2023.

Based on Mangrove Partners's 13F filing for Q3 2023, filed 14 Nov 2023.